Magazine article Information Today

Thomson Acquires Current Drugs, Lawtel

Magazine article Information Today

Thomson Acquires Current Drugs, Lawtel

Article excerpt

Thomson Corp. has announced that it has acquired Current Drugs, Ltd., a privately held U.K.-based provider of integrated competitor intelligence services to the research solutions market. Thomson also announced the acquisition of Lawtel, a U.K.-based legal online information service.

Current Drugs, Ltd.

Current Drugs provides databases, systems, and services such as the Investigational Drugs database (IDdb), a resource for scientists and business executives involved in drug research and development. Financial terms of the agreement were not disclosed.

According to the announcement, the addition of Current Drugs enhances the offerings that Thomson provides to the drug discovery and development functions within pharmaceutical and biotechnology companies. When combined with other Thomson products and businesses such as Derwent World Patent Index, Derwent GENESEQ, and ISI Web of Science, as well as the workflow capabilities of Wila Verlag, Current Drugs further enables Thomson to deliver a highly differentiated, comprehensive research solution to the pharmaceutical and biotechnology market.

"This is a very exciting development for all involved," said Mike Tansey, CEO of Thomson Scientific. "Thomson brings to Current Drugs the additional expertise, must-have content, and infrastructure needed to grow the business and meet the expanding needs of its customers. And with the addition of this business, Thomson will soon be able to offer a range of databases and services on the IDdb platform that will help customers achieve improved productivity in their R&D organizations."

Current Drugs' IDdb delivers content in a manner that enables integration with a client's own proprietary data and supports the researcher work flow by using a proprietary thesaurus. Current Drugs also provides products that focus on specific areas of scientific research, including the review journal Current Opinion in Drug Discovery and Development and patent-based competitor intelligence services for the biopharmaceutical sector. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.